Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11240031 | 0.85 | — | — | |
| SCHEMBL2210250 | 0.78 | MAPK1 (0.32) | MAPK1MEN1KMT2A | |
| SCHEMBL15692308 | 0.74 | CRBN (0.38) | CRBNSMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL10232389 | 0.74 | CRBN (0.38) | CRBNSMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL12687558 | 0.73 | — | — | |
| SCHEMBL339946 | 0.73 | — | — | |
| SCHEMBL10934052 | 0.73 | — | — | |
| SCHEMBL10934045 | 0.73 | — | — | |
| SCHEMBL2611974 | 0.73 | — | — | |
| SCHEMBL3664749 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | PURDUE PHARMA L.P. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3409659-B1 | ADAMANTANE DERIVATIVE AND USE THEREOF | UNIV TOHOKU (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-07-16 | — | — | US | disclosed |
| US-20180370971-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. | 2018-12-27 | — | — | US | disclosed |
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. | 2018-05-31 | — | — | US | disclosed |
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. | 2018-05-31 | — | — | US | disclosed |
| US-9951038-B2 | Quinazolin-4(3H)-one-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9890164-B2 | Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators | PURDUE PHARMA, L.P. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2654751-B1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA LP (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160009717-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | disclosed |
| EP-2324013-B3 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140187544-A1 | OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| WO-2014102592-A2 | OXIME/SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20130274265-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2013-10-17 | — | — | US | disclosed |
| US-8476271-B2 | Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators | PURDUE PHARMA, L.P. (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2537844-A1 | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | Purdue Pharma L.P. (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2324013-B1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2011-07-21 | — | — | US | disclosed |
| EP-2324013-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010010458-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | QDPR, P2RX4, P2RX5 | CRBN 4274/4885SMN1; SMN2 1041/4885MAPK1 1874/4885 |
| US-20130274265-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | OPRK1, OPRD1, P2RX4 | CRBN 3563/4885SMN1; SMN2 471/4885MAPK1 2239/4885 |
| US-20160009717-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | OPRK1, OPRD1, P2RX4 | CRBN 3563/4885SMN1; SMN2 471/4885MAPK1 2239/4885 |
| US-20180370971-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | P2RX4, OPRK1, QDPR | CRBN 3699/4885SMN1; SMN2 571/4885MAPK1 2476/4885 |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, OPRK1, QDPR | CRBN 3699/4885SMN1; SMN2 571/4885MAPK1 2476/4885 |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | OPRK1, OPRD1, P2RX4 | CRBN 3563/4885SMN1; SMN2 471/4885MAPK1 2239/4885 |
| US-20140187544-A1 | OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QSOX1, OPRK1, OPRD1 | CRBN 4010/4885SMN1; SMN2 466/4885MAPK1 2649/4885 |
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | P2RX4, OPRK1, QDPR | CRBN 3699/4885SMN1; SMN2 571/4885MAPK1 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.